top of page
Rechercher

USA : ARMED FORCES PRESS REVELE DES FAITS CHOQUANTS


Le Armed Forces Press est le premier journal d'investigation de l'armée américaine.

Le 5 janvier 2023, elle a publié un article choquant sur la forte implication du Ministère de la Défense (DoD ) dans le programme du vaccin Covid-19.


"De nouveaux documents révèlent que le ministère de la Défense a contrôlé le programme COVID-19 dès le début.


Le processus d'approbation du vaccin par la FDA était une pièce de théâtre.


Une combinaison de la loi PREP, de l'autorisation d'utilisation d'urgence et d'autres autorisations de transaction (OTA) a protégé de toute responsabilité les grandes entreprises pharmaceutiques, les agences et les participants médicaux qui ont fourni des vaccins non réglementés.


D'après les lois votées par le Congrès, les recherches sur les lois en vigueur et les détails supplémentaires obtenus par le biais de la loi sur la liberté d'information, le ministère de la Défense possède, met en œuvre et supervise le programme de vaccination COVID-19 en tant que "contre-mesure" à une attaque extérieure.


Selon les rapports de l'Operation Warp Speed/ASPR, le DoD a ordonné, supervisé et géré étroitement le développement, la fabrication et la distribution des contre-mesures Covid, en utilisant principalement le réseau précédemment établi de contractants et de consortiums militaires du DoD.


Le ministère de la Défense, la BARDA et le HHS ont commandé toutes les contre-mesures Covid, y compris les "vaccins", en tant que prototypes de démonstration de fabrication à grande échelle, en évitant les réglementations et la transparence dans le cadre de l'Other Transaction Authority ( OTA ). En tant que prototypes utilisés dans le cadre de l'EUA au cours de l'EPS, les contre-mesures Covid, y compris les "vaccins", n'ont pas à respecter les lois américaines en matière de qualité de fabrication, de sécurité et d'étiquetage.


"L'implication est que le gouvernement américain a autorisé et financé le déploiement de matériel biologique non conforme sur des Américains sans clarifier leur statut légal de "prototype", rendant le matériel non soumis à la surveillance réglementaire normale, tout en maintenant une présentation pseudo "réglementaire" frauduleuse au public".

"Le plus incroyable est le fait que les lois actuelles promulguées par le Congrès des États-Unis semblent rendre ces actions de dissimulation LÉGALES.


Le peuple américain a été amené à croire que la FDA, le CDC et des figures de proue comme Anthony Fauci supervisaient le programme du vaccin COVID-19. Leur implication était une opération d'information orchestrée. Toutes les décisions concernant la recherche sur le vaccin COVID-19, l'acquisition de matériel, la distribution et le partage d'informations étaient étroitement contrôlées par le DoD.


Des centaines de contrats de contre-mesures Covid ont été découverts, et leur examen révèle un haut degré de contrôle de la part du gouvernement américain (DoD/BARDA). Il spécifie la portée des livrables comme étant uniquement des "démonstrations" et des "prototypes" tout en excluant les essais cliniques et le contrôle de la qualité de fabrication de la portée des travaux payés par les contrats. Afin de garantir que l'entreprise pharmaceutique soit libre de procéder à de faux essais cliniques sans risque financier, les contrats prévoient la suppression de toute responsabilité pour les fabricants et tous les contractants de la chaîne d'approvisionnement et de distribution en vertu de la loi PREP de 2005 et de la législation fédérale connexe.


Une importante opération d'information a été mise en place à la minute où le COVID-19 a frappé. Le gouvernement américain, la communauté du renseignement, les médias et les grandes entreprises technologiques se sont concertés pour orchestrer et mettre en œuvre une intense campagne de pression destinée à obtenir la désignation légale du vaccin en vertu de la loi d'autorisation d'utilisation d'urgence, tout en diffamant les médecins dissidents, les critiques et les traitements alternatifs viables. Cette désignation a permis une fabrication rapide sans tenir compte des protocoles standard de sécurité et de santé publique.


Pour qu'un vaccin soit désigné en vertu de l'EUA, il ne peut y avoir d'autres traitements ou remèdes connus. Par conséquent, de nombreux traitements éprouvés, tels que l'ivermectine et l'hydroxychloroquine, ont été mis à l'index par les médias et qualifiés de "vermifuges pour chevaux", alors que ces médicaments bon marché et facilement disponibles étaient autrefois réputés pour leur efficacité.



Pardon ????


Pour l'examen desdits contrats cliquez ici :

  • Advanced Technology International (ATI) – Underlying contract to execute MCDC and COVID-19 contracts on behalf of the federal government.

  • DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016.

  • DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016. (Version obtained November 30, 2020 from HHS FOIA Reading Room)


  • Aerpio – respiratory condition treatment.

  • DOD-Aerpio Statement of Work W81XWH1590001.

  • DOD-Aerpio Project Approval Letter W81XWH1590001. July 28, 2020.


  • Altimmune – therapeutic.

  • DoD-Altimmune Project Approval Letter W81XWH159001. June 17, 2020.

  • DoD-Altimmune Statement of Work W81XWH159001.

  • DoD-Altimmune Revised Project Approval Letter (3) W81XWH159001. February 3, 2021.

  • DoD-Altimmune Revised Project Approval Letter (2) W81XWH159001. December 15, 2020.


  • America’s Blood Center – convalescent plasma.

  • HHS/ASPR/BARDA-America’s Blood Center Contract 75A50120000094 (includes Mods 1-8). April 17, 2020.

  • DOD-America’s Blood Centers Contract W911QY2190006. October 30, 2020.


  • ANP Technologies – diagnostics.

  • DoD-ANP Technologies Contract W911QY20D0019 (includes Mods 1-3). May 29, 2020.

  • DOD-ANP Technologies Supply Order W911QY20D0019 (includes Mods 1-3). June 2, 2020.

  • DOD-ANP Technologies Supply Order W911QY20P0141 (includes Mod 1). April 17, 2020.


  • AstraZeneca – vaccine.

  • HHS/ASPR/BARDA-AstraZeneca Advanced Agreement to Other Transaction Authority Agreement 75A501-20-C-00114. May 20, 2020.

  • HHS/ASPR/BARDA-AstraZeneca Modification of OTA Agreement 75A501-20-C-00114 MODP00001. July 31, 2020.


  • AstraZeneca – vaccine.

  • DoD-AstraZeneca Other Transaction Authority Agreement W15QKN2191003. October 28, 2020.


  • AstraZeneca – prophylactic monoclonal antibody.

  • DOD-AstraZeneca Contract W911QY2190001 (includes Mods 1, 2, 3, and 5). October 9, 2020.


  • AstraZeneca – therapeutic.

  • DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020.

  • DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020. (Version obtained by FOIA)


  • Atlantic Diving Supply – no-contact thermometers.

  • DOD-Atlantic Diving Supply Contract W911QY18D0019. September 16, 2020.


  • Beckman Coulter – diagnostic-related.

  • HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078. September 30, 2019.

  • HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078-P00001. May 15, 2020.

  • HHS/ASPR/BARDA-Beckman Coulter Contract 75A50120C00189. September 28, 2020.


  • Biofire Defense – diagnostics.

  • DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0271. April 24, 2020.

  • DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0171 (includes Mods 1-2). May 23, 2020.

  • DOD-Biofire Defense Supply Order W911QY20F0196 and W911QY20F0165 Contract W911QY13D0080 (includes Mod 1 of W911QY20F0196). April 17, 2020.


  • BCG Federal Corp – COVID-19-related support services.

  • DoD-BCG Federal Corp Contract W911QY20P0198. June 28, 2020.


  • Centivax – therapeutic.

  • DOD-Centivax Statement of Work W81XWH1590001.

  • DOD-Centivax Project Approval Letter W81XWH1590001. August 19, 2020.


  • Cepheid – test kits.

  • DoD-Cepheid Contract W911QY20C0046 (includes Mods 1, 2, 3, 5, and 6). April 5, 2020.

  • DoD-Cepheid Contract W911QY20P0154 (includes Mods 1-6). April 27, 2020.

  • DoD-Cepheid Contract W911QY20P0195 (includes Mod 2). June 12, 2020.

  • DoD-Cepheid Technical Direction Letter W15QKN1691002. September 14, 2020.

  • DOD-Cepheid Contract W911QY20C0124 (includes Mods 1-5, Supply Order W911QY21F0116 (January 22, 2021) + 1 Mod, and Supply Order W911QY21F0205 (March 25, 2021)). September 24, 2020.


  • ChemBio Diagnostic – antigen test.

  • HHS/ASPR/BARDA-ChemBio Diagnostic Contract 75A50120C00138. July 3, 2020.

  • HHS/ASPR/BARDA-ChemBio Diagnostic Contract 75A50120C00138-P00001. July 20, 2020.


  • Controlant – services.

  • DoD-Controlant Contract W911QX21C0010 (includes Mods 1-4). November 25, 2020.

  • DoD-Controlant Contract W911QX21C0010 Mods 5, 7, and 8. May 10, 2021.


  • Corning Incorporated – vaccine manufacturing supplies.

  • DoD-Corning Contract W911NF2030004. June 5, 2020.


  • Cue Health – diagnostics manufacturing supplies.

  • DoD-Cue Health Other Transaction Authority Agreement W911NF2190001. October 13, 2020.


  • Cue Health – diagnostics.

  • HHS-Cue Health Contract HHSO100201800016C. June 4, 2018.

  • HHS-Cue Health Contract HHSO100201800016C-P00001. September 1, 2019.

  • HHS-Cue Health Contract HHSO100201800016C-P00002. March 21, 2020.

  • HHS-Cue Health Contract HHSO100201800016C-P00003. May 13, 2020.

  • HHS-Cue Health Contract HHSO100201800016C-P00004. September 22, 2020.


  • Culmen – PPE.

  • DOD-Culmen International Contract W911QY18D0042 (includes Mods 1-8). April 22, 2020.


  • Cytiva (Global Life Sciences Solutions) – vaccine manufacturing supplies.

  • DoD-Cytiva Contract W911NF2130001 (includes Mod 1). October 13, 2020.


  • Cytovale – COVID-related sepsis assessment.

  • HHS-Cytovale Contract 75A50119C00072. September 28, 2019.

  • HHS-Cytovale Contract 75A50119C00072-P00001. April 7, 2020.


  • Diasorin – assays.

  • HHS/ASPR/BARDA-DiaSorin Contract 75A50120C00017. March 11, 2020.


  • Diomics Corporation – diagnostics.

  • DoD-Diomics Corporation Project Approval Letter W81XWH159001. August 17, 2020.

  • DoD-Diomics Corporation Revised Project Approval Letter W81XWH159001. February 2, 2021.

  • DoD-Diomics Corporation Statement of Work W81XWH159001.


  • Eli Lilly – therapeutic.

  • DoD-Eli Lilly Contract W911QY21C0016 (includes Mods 1-5). October 27, 2020.

  • DOD-Eli Lilly Contract W911QY21D0012-P00002. April 7, 2021.

  • DOD-Eli Lilly Contract W911QY21F0167-P00003. May 27, 2021.


  • Emergent Biosolutions – convalescent plasma manufacturing and clinical studies.

  • DOD-Emergent Biosolutions Canada Contract W911QY2090013 (includes Mod 1). June 24, 2020.


  • Emergent Biosolutions – vaccine manufacturing.

  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I. June 15, 2012. (Version obtained via SEC filing)

  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I -Task Order 75A50120F33007. May 24, 2020. (Version obtained via SEC filing)

  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I -Task Order 75A50120F33007. May 24, 2020. (Version obtained via FOIA)

  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I-75A50120F33007-P00001. August 24, 2020.

  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I-75A50120F33007-P00002. May 13, 2020.

  • HHS/ASPR/BARDA-Emergent Biosolutions Contract HHSO100201200004I-75A50120F33007-P00003. October 7, 2020.


  • Emory University – therapeutic.

  • DoD (via ATI)–Emory University Technical Direction Letter Other Transaction Authority W15QKN1691002. July 1, 2020.


  • Empatica – diagnostics technology.

  • HHS/ASPR/BARDA-Empatica Contract 75A50120C00132. June 18, 2020.


  • Empatica – diagnostics technology.

  • DoD-Empatica Project Approval Letter W81XWH159001. September 10, 2020.

  • DoD-Empatica Statement of Work W81XWH159001.


  • Evidation Health – COVID-19 detection and forecasting model.

  • HHS/ASPR/BARDA-Evidation Health Contract 75A50120C00091. April 17, 2020.


  • Federal Resources Supply – collection kits.

  • DOD-Federal Resources Supply Contract W911QY18D0060 – Order W911QY20F0215 (includes Mods 1-2). April 24, 2020.

  • DOD-Federal Resources Supply Contract W911QY18D0060 – Order W911QY20F0226 (includes Mods 1-3). May 4, 2020.

  • DOD-Federal Resources Supply Contract W911QY18D0060 – Order W911SR20F0039 (includes Mods 1-5). April 22, 2020.


  • Fitbit – diagnostics technology.

  • DoD-Fitbit Project Approval Letter W81XWH1590001. September 23, 2020.

  • DoD-Fitbit Statement of Work W81XWH1590001.


  • Flir – thermometers.

  • DOD-Flir Commercial Contract W911QY20P0149. April 22, 2020.


  • Fujifilm – therapeutic.

  • DoD (via ATI)–Fujifilm Project Approval Letter 2009COVID19006 under Other Transaction Authority Agreement W81XWH1590001. July 9, 2020.

  • DoD (via ATI)–Fujifilm Revised Project Approval Letter 2009COVID19006 under Other Transaction Authority Agreement W81XWH1590001. December 14, 2020.

  • DoD (via ATI)–Fujifilm Statement of Work 2009COVID19006 under Other Transaction Authority Agreement W81XWH1590001. December 14, 2020.


  • Genentech (Roche) -therapeutic.

  • HHS/ASPR/BARDA-Genentech Other Transaction Authority Agreement HHSO100201800036C. September 27, 2018.

  • HHS/ASPR/BARDA-Genentech Modification of OTA Agreement HHSO100201800036C. March 27, 2020.


  • GenMark Diagnostics – diagnostic.

  • HHS/ASPR/BARDA-GenMark Diagnostics Contract 75A50120C00022. March 20, 2020.

  • HHS/ASPR/BARDA-GenMark Diagnostics Contract 75A50120C00022-P00001. May 28, 2020.

  • HHS/ASPR/BARDA-GenMark Diagnostics Contract 75A50120C00022-P00002. July 20, 2020.


  • GlaxoSmithKline – vaccines.

  • DoD/ASPR/BARDA-GlaxoSmithKline Contract W15QKN20C0048. July 30, 2020.

  • DoD/ASPR/BARDA-GlaxoSmithKline Contract W15QKN20C0048-P00001. July 30, 2020.

  • DoD/ASPR/BARDA-GlaxoSmithKline Contract W15QKN20C0048-P00002. September 16, 2020



  • Global Life Sciences – vaccine supply manufacturing.

  • DOD-Global Life Sciences Solution Contract W911NF2130001 P00003. July 29, 2021.


  • Golden Max – infusion pump kits.

  • DoD-Golden Max Contract W81XWH20D0057 (includes Mod 1). April 17, 2020.


  • Grifols Therapeutics – convalescent plasma.

  • DoD (via ATI)-Grifols Therapeutics Technical Direction Letter Other Transaction Authority Agreement W15QKN1691002. September 1, 2020.


  • Grand River Aseptic Manufacturing (GRAM) – vaccine and therapeutic manufacturing.

  • DoD-Grand River Aseptic Manufacturing (GRAM) Contract W3110Y2OCC086-P00003. August 4, 2020.

  • DoD-Grand River Aseptic Manufacturing (GRAM) Contract W3110Y2OCC086 – Mods 3 and 1-5. August 4, 2020. (Version obtained via FOIA)

  • DoD-Grand River Aseptic Manufacturing (GRAM) Contract W3110Y2OCC086 Mods 1-5. September 1, 2020.


  • Hologic – testing assays.

  • HHS/ASPR/BARDA-Hologic Contract 75A50120P00069. April 29, 2020.

  • HHS/ASPR/BARDA-Hologic Contract 75A50120P00100. August 7, 2020.

  • HHS/ASPR/BARDA-Hologic Contract 75A50120P00100-P00001. October 29, 2020.


  • Icon – clinical trials.

  • DoD-Icon Other Transaction Authority Agreement W911QY2090007 (includes Mods 1 and 4). April 27, 2020.


  • IIT Research Institute – tech transfer for virus neutralization assay.

  • DOD-IIT Research Institute Contract W911QY21C0014. November 30, 2020.


  • Immunome – antibody-related (redactions).

  • DOD-Immunome Contract W911QY2090019. July 3, 2020.


  • Inbios International – diagnostics.

  • DoD-Inbios International Contract W81XWH20F0253 (includes Mod 1). June 15, 2020.


  • Inbios – antibody diagnostic.

  • HHS-InBios Contract 75A50120C00090. April 26, 2020.


  • Inhalon Biopharma – inhaled prevention/therapeutic.

  • DoD-Inhalon Biopharma Project Approval Letter W81XWH1590001. September 11, 2020.

  • DoD-Inhalon Biopharma Statement of Work W81XWH1590001.


  • Inovio Pharmaceuticals – vaccine delivery.

  • DoD-Inovio Pharmaceuticals Contract W911QY20C0084. June 18, 2020. (Version obtained from SEC filings)

  • DoD-Inovio Pharmaceuticals Contract W911QY20C0084. June 18, 2020. (Version obtained via FOIA request)

  • DoD-Inovio Pharmaceuticals Other Transaction Authority Agreement W911QY2090016. June 22, 2020. (Version obtained from SEC filings)

  • DOD-Inovio Pharmaceutical Other Transaction Authority Agreement W911QY2090016. June 22, 2020. (Version obtained via FOIA request)


  • Johns Hopkins University – clinical trials of convalescent plasma.

  • DOD-Johns Hopkins University Other Transactions Authority Agreement W911QY2090012 (includes Mod 5). June 8, 2020.


  • Johnson&Johnson (Janssen) – vaccine.

  • HHS/ASPR/BARDA-Janssen Other Transaction Authority Agreement HHSO100201700018C. August 15, 2017. (Version obtained by FOIA March 31, 2021).

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 6. February 11, 2020.

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 6. February 11, 2020. (Version obtained by FOIA March 31, 2021).

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 7. March 20, 2020.

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 8. March 27, 2020.

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 8. February 11, 2020. (Version obtained by FOIA March 31, 2021).

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendments 1, 2, 3 (dates redacted) 4 (date not listed), 5 (December 19, 2019), 9 (date not listed), 10 (August 21, 2020). (Version obtained by FOIA June 2021)

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 6. February 11, 2020. (Version obtained by FOIA June 2021)


  • Johnson&Johnson (Janssen) – therapeutic.

  • HHS/ASPR/BARDA-Janssen Other Transaction Authority Agreement HHSO100201800012C. September 21, 2018.

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201800012C-Amendment 1. April 4, 2019.

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201800012C-Amendment 2. August 1, 2019.

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201800012C-Amendment 3. January 31, 2020.

  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201800012C-Amendment 4. February 14, 2020.

  • HHS/ASPR/BARDA-Janssen Other Transaction Authority Agreement HHSO100201800012C. September 21, 2018. (Version obtained via FOIA June 2021)


  • Johnson&Johnson (Janssen) – vaccine.

  • DoD (via ATI)-Janssen Other Transaction Authority Agreement W15QKN1691002-P00081. August 5, 2020.

  • DoD (via ATI)-Janssen Other Transaction Authority Agreement W15QKN1691002-P00081-Mod00001. September 21, 2020. (Version obtained by FOIA)


  • Just Evotec – therapeutic manufacturing.

  • DOD-Just Evotec Contract W911QY2090015 (includes Mods 1-3). July 7, 2020.


  • Kalman – labor support services.

  • DOD-Kalman W911QY19F0147-P00042. March 1, 2021.


  • KPMG – prototype process for mAb infusion capacity.

  • DOD-KPMG W912CG2190001-P00001. June 16, 2021.


  • Lumen Bioscience – therapeutic.

  • DoD-Lumen Bioscience Project Approval Letter W81XWH1590001. July 24, 2020.

  • DoD-Lumen Bioscience Revised Project Approval Letter (2) W81XWH1590001. August 11, 2020.

  • DoD-Lumen Bioscience Revised Project Approval Letter (3) W81XWH1590001. December 9, 2020.

  • DoD-Lumen Bioscience Revised Project Approval Letter (4) W81XWH1590001. February 4, 2021.

  • DoD-Lumen Bioscience Statement of Work W81XWH1590001.


  • Luminex – antibody assay.

  • HHS/ASPR/BARDA-Luminex Contract 75A50120C00179. September 23, 2020.

  • HHS/ASPR/BARDA-Luminex Contract 75A5012C00037. March 26, 2020.

  • HHS/ASPR/BARDA-Luminex Contract 75A50120C00043. March 27, 2020.


  • Maxim – diagnostics.

  • DoD-Maxim Contract W911QY20D0018 (includes Mods 1-4). May 11, 2020.


  • MBio – antibody diagnostic.

  • HHS-MBio Diagnostics Contract 75A50120C00130. June 17, 2020.


  • Merck Sharp & Dohme – vaccine.

  • (Note: HHSO100201600031C began as a contract to Bioprotection Systems for an Ebola vaccine, Merck entered into a collaboration agreement with BPS in 2014)

  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C. September 29, 2016.

  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-Attachment 2-Milestones. May 19, 2017.

  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-Attachment 1-Statement of Work. May 19, 2017.

  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-P00001. April 27, 2017.

  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-P00002. September 6, 2017.

  • HHS/ASPR/BARDA–Bioprotection Systems Corporation Contract HHSO100201600031C-P00003. May 23, 2018.

  • HHS/ASPR/BARDA-Merck Sharp & Dohme Contract Amendment HHSO100201600031C-P00004. May 9, 2019.

  • HHS/ASPR/BARDA-Merck Sharp & Dohme Contract Amendment HHSO100201600031C-P00005. April 14, 2020. (Version obtained March 2021 via FOIA lawsuit)

  • HHS/ASPR/BARDA-Merck Sharp & Dohme Contract Amendment HHSO100201600031C-P00005. April 14, 2020.


  • Merck Sharp & Dohme – therapeutic.

  • DoD-Merck Sharp & Dohme Other Transaction Authority Agreement W911QY2190001. December 2, 2020.


  • Merck Sharp & Dohme – therapeutic.

  • DOD-Merck Sharp & Dohme Contract W911QY21C0031. June 7, 2021.


  • Microbiologics – tech transfer for virus neutralization assay.

  • DOD-Microbiologics Contract W911QY21C0012 (includes Mod 1). November 9, 2020.


  • Minnesota Medical Warehouse – hand sanitizer.

  • DOD-Minnesota Medical Warehouse Contract W911SR20P0010 (includes Mods 1-3). April 30, 2020.


  • Moderna – vaccine.

  • HHS/ASPR/BARDA-Moderna Contract 75A50120C00034. April 16, 2020.

  • HHS/ASPR/BARDA-Moderna Contract 75A50120C00034. April 16, 2020. (Less redacted version obtained via FOIA lawsuit on February 8, 2021)

  • HHS/ASPR/BARDA-Moderna Contract 75A50120C00034-P00003. July 25, 2020.


  • Moderna – vaccine manufacturing.

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained from Moderna SEC filings)

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained October 29, 2020 from HHS FOIA Reading Room)

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained November 9, 2020 from HHS FOIA Reading Room)

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100-P00001. August 9, 2020.

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100-P00002. September 11, 2020.

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100-P00003. December 11, 2020.

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100-P00004. February 11, 2021. (Obtained via FOIA)

  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100 – Mods 7-10. June 15, 2021.


  • MRI Global – mobile medical laboratories.

  • DOD-MRI Global Contract W911SR20F0054 – Mods 1-2. May 27, 2020.


  • Murtech – diagnostics.

  • DoD-Murtech Contract W911QY20D0017 (includes Mods 1-2). May 11, 2020.


  • Nanomix – antibody diagnostics.

  • HHS/ASPR/BARDA-Nanomix Contract 75A50120C00060. April 2, 2020.

  • HHS/ASPR/BARDA-Nanomix Contract 75A50120C00060-P00001. June 19, 2020.

  • HHS/ASPR/BARDA-Nanomix Contract 75A50120C00060-P00002. July 24, 2020.


  • New Horizons Diagnostics Corp. – diagnostic.

  • DOD (via ATI)-New Horizons Diagnostics Technical Direction Letter Other Transaction Authority Agreement W15QKN1691002 (includes updated TDL). May 26, 2020.


  • Novavax – vaccine.

  • DoD-Novavax Contract W911QY20C0077 (includes Mod 1). June 4, 2020.

  • DoD-Novavax Contract W911QY20C0077 – Mods 1-4. June 4, 2020.


  • Novavax – vaccine.

  • DoD (via ATI)-Novavax Other Transaction Authority Agreement W15QKN1691002. June 25, 2020. (Version obtained via SEC filing)

  • DoD (via ATI)-Novavax Technical Direction Letter W15QKN1691002. July 6, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)

  • DoD (via ATI)–Novavax Statement of Work W15QKN1691002. (Version obtained via FOIA lawsuit)

  • DoD (via ATI)–Novavax Technical Direction Letters and Statements of Work W15QKN1691002. July 6, 2020 and December 21, 2020. (Version obtained via FOIA lawsuit)


  • NOWDiagnostics – diagnostics.

  • HHS/ASPR/BARDA-NOWDiagnostics Contract 75A50120C00156. August 27, 2020.


  • Ology Bioservices (previously called Nanotherapeutics, Inc.) – vaccine manufacturing.

  • DoD-Ology Bioservices Other Transaction Authority Agreement-W911QY2090003 Contract and Mods 1-5,8-10,12,14,15,17,23-25 . February 21, 2020

  • DoD-Ology Bioservices Other Transaction Authority Agreement OTA-W911QY2090003. February 21, 2020.

  • DoD-Ology Bioservices Other Transaction Authority Agreement Appendix OTA-W911QY2090003-Appendix-A-4. March 20, 2020.

  • DoD-Ology Bioservices Contract W911QY2090003-MOD-P00005. March 22, 2020.


  • Ology Bioservices (previously called Nanotherapeutics, Inc.) – vaccine manufacturing.

  • DoD-Ology Bioservices Contract W911QY20C0101 (includes Mod 1). August 17, 2020.


  • Ophirex – therapeutic.

  • DoD-Ophirex Contract W81XWH20C0066 (includes Mods 1-3). June 19, 2020.


  • Orasure – rapid antigen test.

  • HHS/ASPR/BARDA-Orasure Contract 75A50120C00061. Date not listed.

  • HHS/ASPR/BARDA-Orasure Contract 75A50120C00122. May 27, 2020.


  • Ortho Clinical – antibody assays.

  • HHS/ASPR/BARDA-Ortho Clinical Contract 75A50120C00123. June 12, 2020.

  • HHS/ASPR/BARDA-Ortho Clinical Contract 75A50120C00123-P00001. August 28, 2020.

  • HHS/ASPR/BARDA-Ortho Clinical Contract 75A50120P00103. September 18, 2020.


  • Oxford Nanopore Technologies – DNA sequencing.

  • DoD-Oxford Nanopore Technologies Contract W911QX20P0073 (includes Mod 1). April 22, 2020.


  • Partner Therapeutics, Inc. – therapeutic.

  • DOD (via ATI)-Partner Therapeutics Technical Direction Letter OTA W15QKN1691002. August 13, 2020.


  • Patricio Enterprises – COVID-19 mobile lab staffing.

  • DoD-Patricio Enterprises Supply Order W911QY2OF0270-P00001 Contract W911QY18D0251. June 3, 2020.

  • DOD-Patricio Enterprises Contract W911QY19F0133-P00037. December 7, 2020.


  • Pfizer – vaccine.

  • DoD (via ATI)-Pfizer Technical Direction Letter OTA W15QKN1691002. July 21, 2020.


  • Pfizer – vaccines.

  • DoD-Pfizer Contract W15QKN21C0012 (includes Mod 310). December 22, 2020.


  • Pfizer – manufacturing.

  • DVA-Pfizer Contract V797D40269-P00376. June 1, 2021.


  • Pfizer – vaccine donation.

  • DoD-Pfizer Contract W58P0521C0002. July 30, 2021.

  • DOD-Pfizer Contract W58P0521C0002 Contract and P00376. July 30, 2021.


  • Pharm Olam – therapeutic clinical trial.

  • DOD-Pharm Olam Contract W911QY2190014. December 31, 2020.


  • Philips North America – diagnostics technology.

  • HHS/ASPR/BARDA-Philips North America Contract 75A50120C00097. May 7, 2020.

  • DoD-Philips North America Project Approval Letter W81XWH1590001. August 27, 2020.

  • DoD-Philips North America Revised Project Approval Letter (2) W81XWH1590001. September 23, 2020.

  • DoD-Philips North America Revised Project Approval Letter (3) W81XWH1590001. October 13, 2020.

  • DoD-Philips North America Statement of Work W81XWH1590001.


  • Phlow Corporation – therapeutic.

  • HHS/ASPR/BARDA-Phlow Corporation Contract 75A50120000092. May 18, 2020.


  • Plasma Technologies – immune globulin hyperimmune manufacturing.

  • DOD-Plasma Technologies Contract W911QY2020004. August 14, 2020.


  • Protein Sciences Corporation (Sanofi) – vaccine.

  • HHS/ASPR/BARDA-Protein Sciences Corp Contract HHSO100201600005I. February 14, 2020.

  • HHS/ASPR/BARDA-Protein Sciences Corp Contract HHSO100201600005I. August 16, 2016.


  • Qiagen – diagnostic R&D.

  • HHS/ASPR/BARDA-Qiagen Contract 75A50120C00014. March 11, 2020.


  • Quidel – antigen assay R&D.

  • HHS/ASPR/BARDA-Quidel Contract 75A50120C00110. May 29, 2020.


  • Regeneron Pharmaceuticals – therapeutic.

  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C. September 21, 2017.

  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C-MOD0006. January 31, 2020.

  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C-MOD0006. (Date redacted).

  • HHS/ASPR/BARDA-Regeneron Contract HHSO100201700020C-MOD0002. April 22, 2019.

  • HHS/ASPR/BARDA-Regeneron Contract HHSO100201700020C-MOD0003. May 18, 2019.

  • HHS/ASPR/BARDA-Regeneron Contract HHSO100201700020C-MOD0001. September 28, 2018.

  • HHS/ASPR/BARDA-Regeneron Contract HHSO100201700020C-MOD0005. February 12, 2020.

  • HHS/ASPR/BARDA-Regeneron Contract HHSO100201700020C MOD0008. June 15, 2020.

  • HHS/ASPR/BARDA-Regeneron Contract HHSO100201700020C MOD0009. June 19, 2020.

  • HHS/ASPR/BARDA-Regeneron Contract HHSO100201700020C MOD0007. April 29, 2020.


  • Regeneron – therapeutic manufacturing.

  • DoD (via ATI)-Regeneron Other Transaction Authority Agreement W15QKN1691002 (contract and Technical Direction Letter). July 6, 2020.

  • DoD (via ATI–Regeneron Technical Direction Letter W15QKN1691002. July 6, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)


  • Regeneron – prophylactic monoclonal antibody.

  • DOD-Regeneron Pharmaceutical Contract W15QKN21C0014. January 12, 2021.

  • DOD-Regeneron Pharmaceutical Contract W15QKN21C0014-P00004. July 26, 2021.


  • Rigel Pharmaceuticals – therapeutic.

  • DOD-Rigel Pharmaceuticals Other Transaction Authority Agreement W911QY2190018. January 29, 2021.

  • DOD-Rigel Pharmaceuticals Other Transaction Authority Agreement W911QY2190018. January 29, 2021. (Version obtained via FOIA)


  • SAB Biotherapeutics – antibody diagnostic.

  • DOD (via ATI)-SAB Biotherapeutics Technical Direction Letter and Statement of Work – W15QKN1691002. April 18, 2020.


  • Sanofi – vaccine.

  • DOD (via ATI)-Sanofi Technical Direction Letter W15QKN1691002. July 30, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)

  • DOD (via ATI)-Sanofi Technical Direction Letter and Statement of Work RPP20-11 MCDC2011-005. December 18, 2020.


  • Sempulse – diagnostics technology.

  • DoD-Sempulse Project Approval Letter W81XWH1590001. September 23, 2020.

  • DoD-Sempulse Statement of Work W81XWH1590001.


  • Sepsis Alliance – sepsis training.

  • HHS/ASPR/BARDA-Sepsis Alliance Contract HHSO100201900021C. January 19, 2019.

  • HHS/ASPR/BARDA-Sepsis Alliance Contract HHSO100201900021C-P00001. June 6, 2019.

  • HHS/ASPR/BARDA-Sepsis Alliance Contract HHSO100201900021C-P00002. May 7, 2020.


  • Sibel – diagnostics technology.

  • DoD-Sibel Project Approval Letter W81XWH1590001. August 27, 2020.

  • DoD-Sibel Statement of Work W81XWH1590001.


  • Siemens – immunoassay R&D.

  • HHS/ASPR/BARDA-Siemens Contract 75A50120C00111. May 28, 2020.

  • HHS/ASPR/BARDA-Siemens Contract 75A50120C00111-P00001. August 20, 2020.

  • HHS/ASPR/BARDA-Siemens Contract 75A50120P00102. September 17, 2020.


  • SIO2 – domestic pharmaceutical vials.

  • DOD-SIO2 Medical Contract W911NF2030003 (includes Mods 1-3). June 5, 2020.


  • Sonica – diagnostics.

  • HHS/ASPR/BARDA-Sonica Contract 75A50119C00043. August 1, 2019.

  • HHS/ASPR/BARDA-Sonica Contract 75A50119C00043-P00001. February 3, 2020.


  • SourceAmerica – face coverings.

  • DoD-SourceAmerica Contract W911QY20C0047 (includes Mods 1-5). April 17, 2020.

  • DoD-SourceAmerica Contract W911QY20C0047-P00006. November 10, 2020.


  • Tangen – assay.

  • HHS/ASPR/BARDA-Tangen Biosciences Contract 75A50120C00085. April 15, 2020.


  • Tasso – antibody test kits.

  • DoD-Tasso Serology Contract W911QY20P0158 (includes Mods 1-4). May 1, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)

  • DoD-Tasso Serology Contract W911QY20P0158-P00005 and P00006. December 3, 2020. (Version obtained via FOIA)


  • Texas A&M University System – expansion of manufacturing capacity (CIADM related).

  • HHS/ASPR/BARDA-Texas A&M University System Contract HHSO100201200002I-75A50120F33002. July 23, 2020.

  • HHS/ASPR/BARDA-Texas A&M University System Contract HHSO100201200002I-75A50120F33002-P0001. August 27, 2020.

  • HHS/ASPR/BARDA-Texas A&M University System Contract HHSO100201200002I-75A50120F33002-P0002. October 9, 2020.


  • Ultran Group – treatment device.

  • DOD (via ATI)–Ultran Group Technical Direction Letter Other Transaction Authority Agreement W15QKN1691002. September 16, 2020.

  • DOD (via ATI)–Ultran Group Technical Direction Letter Other Transaction Authority Agreement W15QKN1691002. September 16, 2020. (Version obtained via FOIA)


  • University of California at San Francisco – diagnostics technology.

  • DoD-UC San Francisco Project Approval Letter W81XWH1590001. August 5, 2020.

  • DoD-UC-San Francisco Statement of Work and Milestone Payment Schedule W81XWH1590001.


  • University of Connecticut – vaccination technology.

  • HHS/ASPR/BARDA-University of Connecticut Contract 75A50120C00162. August 16, 2020.


  • Vaxess – spike protein vaccine manufacturing.

  • HHS/ASPR/BARDA-Vaxess Technologies Contract 75A50120C00160. August 6, 2020.


  • Vectrus-safety glasses.

  • DOD-Vectrus Mission Solutions Contract W911QY18D0140 (includes Mod 1). April 22, 2020.


  • VelocityDX – diagnostics.

  • DoD-VelocityDX Contract W911QY20D0031. August 12, 2020.

  • DoD-VelocityDX Contract W911QY20D0031. August 12, 2020. (Version obtained via FOIA)


  • Visby – diagnostics.

  • DoD-Visby Medical Contract W911QY20C0110 (includes Mod 1). September 20, 2020.

  • DoD-Visby Medical Contract W911QY20C0110 (includes Mod 1). September 20, 2020. (Version obtained via FOIA)


  • VitalConnect – vital sign threshold settings for COVID-19 patients.

  • HHS/ASPR/BARDA-VitalConnect Contract 75A50120C00108. May 20, 2020.

  • HHS/ASPR/BARDA-VitalConnect Contract 75A50120C00108-P00001. May 20, 2020.


  • VxBiosciences – therapeutic.

  • DoD-VxBiosciences Project Approval Letter W81XWH1590001. July 9, 2020.

  • DoD-VxBiosciences Statement of Work W81XWH1590001.


  • Vyaire Medical, Inc. – ventilators.

  • HHS/ASPR/SNS-Vyaire Medical Contract 75A50120000049 (includes Mod 1). March 31, 2020.


  • Waukesha Foundry – testing swabs.

  • DOD-Waukesha Foundry Contract W911SR20P0009 (includes Mods 1-4). April 17, 2020.


  • World Enterprises – volatile organic compound detection.

  • DOD-World Enterprises W911SR21C0008 (includes Mods 1-3). November 13, 2020.


  • 98Point6 – COVID-related Smartphone technology.

  • HHS-98Point6 Contract 75A50120C001519. October 9, 2020.


US agreements not concerning COVID-19 research, but tied to related vaccine technologies:

  • Moderna – Zika vaccine.

  • HHS/ASPR/BARDA-Moderna Contract HHS0100201600029C. September 1, 2016.


US Government licenses related to COVID-19:

  • NIH/NIAID-Geo Vax – vaccine primes/boosters.

  • NIAID-Geo Vax Nonexclusive Patent License Agreement and Biological Materials License. October 22, 2020.


  • NIH/NIAID-AbCellera Biologics – vaccines and therapeutics.

  • NIAID-AbCellera Patent License Agreement. May 4, 2020.


Europe

  • European Commission-AstraZeneca- vaccine.

  • European Commission-AstraZeneca Advance Purchase Agreement. August 27, 2020.


  • European Commission-Curevac – vaccine.

  • European Commission-Curevac Advance Purchase Agreement.


  • European Commission-Sanofi Pasteur and GlaxoSmithKline – vaccines.

  • European Commission-Sanofi Pasteur and GlaxoSmithKline Advance Purchase Agreement. September 18, 2020.


  • European Investment Bank-BioNTech – financing vaccines.

  • European Investment Bank-BioNTech Finance Contract. June 10, 2020.


  • European Investment Bank-Curevac – financing vaccines.

  • European Investment Bank-Curevac Finance Contract. June 27, 2020.


Australia

  • Australia-Novavax – vaccine.

  • Australia-Novavax Advanced Purchase Agreement. December 31, 2020.


Brazil

  • Fundação Oswaldo Cruz (Fiocruz)-AstraZeneca – vaccine.

  • Fiocruz-AstraZeneca Contract. September 8, 2020.


Canada

  • Canada-Novavax – vaccine.

  • Canada-Novavax Advanced Purchase Agreement. January 19, 2021.


China

  • Beijing Youfeng-Generex – vaccine.

  • NIVDCP-Beijing Youfeng-Generex Contract YF202011-A. November 13, 2020.


Dominican Republic

  • Dominican Republic-Pfizer – vaccine.

  • Dominican Republic-Pfizer Vaccine Term Sheet. January 19, 2021.


Israel

  • Israel Ministry of Health-Pfizer – vaccine.

  • Israel MOH-Pfizer Real-World Epidemiological Evidence Collaboration Agreement. January 6, 2021.


United Kingdom

  • United Kingdom-Novavax – vaccine.

  • United Kingdom-Novavax Supply Agreement. October 22, 2020.


Inter-company Agreements Concerning COVID-19

  • AIM Immuno Tech-Roswell Park Cancer Institute Corporation/Roswell Park Comprehensive Cancer Center – clinical trials.

  • Roswell Park Cancer Institute-AIM Immuno Tech Clinical Trial Agreement. July 6, 2020.


  • AIM Immuno Tech-Amarex – clinical trials.

  • AIM Immuno Tech-Amarex Project Work Order Proposal. August 4, 2020.


  • Amerimmune-Histogen – therapeutics.

  • Amerimmune-Histogen Collaborative Development and Commercialization Agreement. October 26, 2020.


  • Anixa Biosciences-OntoChem – therapeutics.

  • Anixa-OntoChem Collaboration Agreement. April 14, 2020.


  • AbCellera Biologics-Eli Lilly and Company – therapeutics.

  • AbCellera-Eli Lilly Research Collaboration and License Agreement. March 11, 2020.


  • GlaxoSmithKline-Vir Biotechnologies – vaccines and therapeutics.

  • GlaxoSmithKline-Vir Preliminary Collaboration Agreement. April 5, 2020.


  • Hoth Therapetics-George Washington University – smartphone-based direct virus sensing system.

  • Hoth-GWU Sponsored Research Agreement. September 1, 2020.


  • Hoth Therapeutics-Voltron Therapeutics – vaccines.

  • Hoth-Voltron Development and Royalty Agreement. March [redacted], 2020.


  • Kiromic Biopharma-Molipharma – vaccine, therapeutics, and diagnostics.

  • Kiromic-Molipharma Joint Venture Agreement. April 2, 2020.


  • Moderna-Lonza – mRNA vaccines and therapeutics.

  • Moderna-Lonza Global Long Term Agreement. September 4, 2020.


  • Nascent Biotech-Manhattan Biosolutions – vaccines and therapeutics.

  • Nascent-Manhattan Research Collaboration Agreement. April 30, 2020.


  • Novavax-Serum Institute of India – vaccine.

  • Novavax-Serum Institute Supply and License Agreement. July 30, 2020.


  • PharmaCyte Biotech-Hai Kang Life Corporation Limited – diagnostic.

  • PharmaCyte-Hai Kang Life License Agreement. April 2, 2020.


  • Pfizer – BioNTech – vaccine.

  • Pfizer-BioNTech Collaboration Agreement. March 17, 2020.




4 vues0 commentaire

Comments


bottom of page